INO Quote, Financials, Valuation and Earnings

Lexicon Pharmaceuticals has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of -2004.36%. Inovio Pharmaceuticals's return on equity of -125.47% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Inovio Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 279.15%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 211.48%. Given that Inovio Pharmaceuticals has higher upside potential than Lexicon Pharmaceuticals, analysts believe Inovio Pharmaceuticals is more attractive than Lexicon Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.344, which suggesting that the stock is 34.39% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.318%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Inovio Pharmaceuticals's net income of -$19.7M is higher than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 9.26x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of 82.81%. Inovio Pharmaceuticals's return on equity of -125.47% beat Novavax's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 279.15%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 110.64%. Given that Inovio Pharmaceuticals has higher upside potential than Novavax, analysts believe Inovio Pharmaceuticals is more attractive than Novavax.

Inovio Pharmaceuticals has a beta of 1.344, which suggesting that the stock is 34.39% more volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Novavax quarterly revenues of $626.3M. Inovio Pharmaceuticals's net income of -$19.7M is lower than Novavax's net income of $518.6M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Novavax's PE ratio is 2.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 0.87x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of -475.33%. Inovio Pharmaceuticals's return on equity of -125.47% beat Sangamo Therapeutics's return on equity of -269.87%.

Inovio Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 279.15%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.10 which suggests that it could grow by 658%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.344, which suggesting that the stock is 34.39% more volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Sangamo Therapeutics quarterly revenues of $6.4M. Inovio Pharmaceuticals's net income of -$19.7M is higher than Sangamo Therapeutics's net income of -$30.6M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.80x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vaxart has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of -74.68%. Inovio Pharmaceuticals's return on equity of -125.47% beat Vaxart's return on equity of -94.14%.

Inovio Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 279.15%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 843.72%. Given that Vaxart has higher upside potential than Inovio Pharmaceuticals, analysts believe Vaxart is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.344, which suggesting that the stock is 34.39% more volatile than S&P 500. In comparison Vaxart has a beta of 1.255, suggesting its more volatile than the S&P 500 by 25.549%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Vaxart quarterly revenues of $20.9M. Inovio Pharmaceuticals's net income of -$19.7M is lower than Vaxart's net income of -$15.6M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 2.26x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.